Advertisement
Screener

Corvus Pharmaceuticals, Inc. (CRVS) Increase (Decrease) in Other Noncurrent Assets

2.8 / 5 stars · 68/120 Roast Me

Corvus Pharmaceuticals, Inc. Increase (Decrease) in Other Noncurrent Assets

Corvus Pharmaceuticals, Inc. (CRVS) reported Increase (Decrease) in Other Noncurrent Assets of -$180.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06

  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$92.00K.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$88.00K.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$88.00K, a 109.85% decline year-over-year.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was -$85.00K.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was -$338.00K, a 1307.14% decline from fiscal 2024.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was $28.00K.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was -$1.07M.
  • Corvus Pharmaceuticals, Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was -$973.00K.
Period endIncrease (Decrease) in Other Noncurrent Assets 3 monthIncrease (Decrease) in Other Noncurrent Assets 3 month as first filedIncrease (Decrease) in Other Noncurrent Assets 6 monthIncrease (Decrease) in Other Noncurrent Assets 9 monthIncrease (Decrease) in Other Noncurrent Assets 12 monthIncrease (Decrease) in Other Noncurrent Assets 12 month as first filed
2026-06-30-$92.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$180.00K
10-Q · filed 2026-08-06
-$268.00K
derived: sum of 3 quarters · filed 2026-08-06
-$353.00K
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$88.00K
10-Q · filed 2026-05-07
-$176.00K
derived: sum of 2 quarters · filed 2026-05-07
-$261.00K
derived: sum of 3 quarters · filed 2026-05-07
-$344.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$88.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$173.00K
derived: sum of 2 quarters · filed 2026-03-12
-$256.00K
derived: sum of 3 quarters · filed 2026-08-06
-$338.00K
10-K · filed 2026-03-12
2025-09-30-$85.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$168.00K
derived: sum of 2 quarters · filed 2026-08-06
-$250.00K
10-Q · filed 2025-11-04
$643.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$83.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$165.00K
10-Q · filed 2026-08-06
$728.00K
derived: sum of 3 quarters · filed 2026-08-06
$434.00K
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$82.00K
10-Q · filed 2026-05-07
$811.00K
derived: sum of 2 quarters · filed 2026-05-07
$517.00K
derived: sum of 3 quarters · filed 2026-05-07
$230.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$893.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$599.00K
derived: sum of 2 quarters · filed 2026-03-12
$312.00K
derived: sum of 3 quarters · filed 2026-03-12
$28.00K
10-K · filed 2026-03-12
2024-09-30-$294.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$581.00K
derived: sum of 2 quarters · filed 2025-11-04
-$865.00K
10-Q · filed 2025-11-04
-$1.89M
derived: sum of 4 quarters · filed 2026-03-12
2024-06-30-$287.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$571.00K
10-Q · filed 2025-08-07
-$1.60M
derived: sum of 3 quarters · filed 2026-03-12
2024-03-31-$284.00K
10-Q · filed 2025-05-08
-$1.31M
derived: sum of 2 quarters · filed 2026-03-12
2023-12-31-$1.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$1.07M
10-K · filed 2026-03-12
-$40.00K
10-K · filed 2024-03-19
2023-09-30-$40.00K
10-Q · filed 2023-11-07
2022-12-31-$985.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25
-$973.00K
10-K · filed 2025-03-25
-$107.00K
10-K · filed 2023-03-28
2022-09-30$12.00K
10-Q · filed 2023-11-07
2021-12-31-$43.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
-$80.00K
derived: sum of 2 quarters · filed 2024-03-19
-$842.00K
derived: sum of 3 quarters · filed 2024-03-19
-$178.00K
10-K · filed 2024-03-19
2021-09-30-$37.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$799.00K
derived: sum of 2 quarters · filed 2022-11-03
-$135.00K
10-Q · filed 2022-11-03
-$201.00K
derived: sum of 4 quarters · filed 2023-03-28
2021-06-30-$762.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$98.00K
10-Q · filed 2022-08-08
-$164.00K
derived: sum of 3 quarters · filed 2023-03-28
-$185.00K
derived: sum of 4 quarters · filed 2023-03-28
2021-03-31$664.00K
10-Q · filed 2022-05-05
$598.00K
derived: sum of 2 quarters · filed 2023-03-28
$577.00K
derived: sum of 3 quarters · filed 2023-03-28
2020-12-31-$66.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28
-$87.00K
derived: sum of 2 quarters · filed 2023-03-28
-$99.00K
10-K · filed 2023-03-28
2020-09-30-$21.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01
-$33.00K
10-Q · filed 2021-11-01
2020-06-30-$12.00K
10-Q · filed 2021-08-02
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
$0.00
derived: sum of 2 quarters · filed 2022-03-10
-$1.00K
derived: sum of 3 quarters · filed 2022-03-10
$50.00K
10-K · filed 2022-03-10
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
-$1.00K
derived: sum of 2 quarters · filed 2020-10-29
$50.00K
10-Q · filed 2020-10-29
$50.00K
derived: sum of 4 quarters · filed 2021-03-25
2019-06-30-$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$50.00K
10-Q · filed 2020-07-30
$50.00K
derived: sum of 3 quarters · filed 2021-03-25
-$679.00K
derived: sum of 4 quarters · filed 2021-03-25
2019-03-31$51.00K
10-Q · filed 2020-04-30
$51.00K
derived: sum of 2 quarters · filed 2021-03-25
-$678.00K
derived: sum of 3 quarters · filed 2021-03-25
-$549.00K
derived: sum of 4 quarters · filed 2021-03-25
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
-$729.00K
derived: sum of 2 quarters · filed 2021-03-25
-$600.00K
derived: sum of 3 quarters · filed 2021-03-25
-$406.00K
10-K · filed 2021-03-25
2018-09-30-$729.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29
-$600.00K
derived: sum of 2 quarters · filed 2019-10-29
-$406.00K
10-Q · filed 2019-10-29
2018-06-30$129.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$323.00K
10-Q · filed 2019-08-01
2018-03-31$194.00K
10-Q · filed 2019-05-09
2017-09-30$189.00K
10-Q · filed 2018-11-01
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$250.00K
derived: sum of 2 quarters · filed 2019-03-07
$269.00K
derived: sum of 3 quarters · filed 2019-03-07
$869.00K
10-K · filed 2019-03-07
2016-09-30$250.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02
$269.00K
derived: sum of 2 quarters · filed 2017-11-02
$869.00K
10-Q · filed 2017-11-02
2016-06-30$19.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
$619.00K
10-Q · filed 2017-08-03
2016-03-31$600.00K
10-Q · filed 2017-05-04
-$600.00K
10-Q · filed 2016-05-05
2015-09-30-$252.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
-$212.00K
derived: sum of 2 quarters · filed 2016-11-03
-$232.00K
10-Q · filed 2016-11-03
2015-06-30$40.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$20.00K
10-Q · filed 2016-08-04
2015-03-31-$20.00K
10-Q · filed 2016-05-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Savara Inc (SVRA)United States$1.044B-9.10
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Apnimed, Inc. (APMD)United States$0.899B